USA-based Kedrion Biopharma has announced that Ryplazim (plasminogen, human-tvmh) is in stock and available for purchase in the USA.
The US regulator announced in mid-2023 that the product was being provided “in a very limited supply” and would soon be out of stock.
The resumption of supply will be welcomed by the approximately 500 people in the USA with plasminogen deficiency type 1 (PLGD-1), an ultra-rare disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze